BURST CME™ in ALS: Streamlining the Pathway From Research to Treatment

Released On
March 23, 2021

Expires On
March 23, 2022

Media Type
Internet

Completion Time
60 minutes

Specialty
Neurology

Topic(s)
Parkinson's & Movement Disorders

Scroll to the Bottom of this Information to Begin this Course

This activity is provided by Physicians’ Education Resource®, LLC.

This activity is supported by an educational grant from Mitsubishi Tanabe Pharma America, Inc.

Credit Available

  • Physicians — maximum of 1.0 AMA PRA Category 1 Credit(s)

All other health care professionals completing this course will be issued a statement of participation.

Target Audience

This online educational activity is directed toward neurologists, internists, and other health care professionals involved in the treatment of patients with amyotrophic lateral sclerosis (ALS), such as PCPs, NPs, and PAs.

Activity Overview

This online activity is designed to provide a concise overview of treatment options for amyotrophic lateral sclerosis (ALS) and best practices for therapeutic decision-making. It covers ALS pathophysiology, discusses the clinical presentation and diagnostic evaluation in this setting, emphasizes the importance of multidisciplinary care, and evaluates the efficacy and safety of agents that modify the disease course of ALS. We also take a brief look at the future of gene therapy. This engaging, multimedia program integrates audio commentary from an expert thought leader, Terry Heiman-Patterson, MD, with text-based elements.

Learning Objectives

Upon successful completion of this activity, you should be better prepared to:

  • Describe the clinical relevance of genetic mutations involved in the etiology of ALS and discuss the challenges of accurate and timely diagnosis
  • Evaluate the efficacy and safety of currently approved disease-modifying and symptom-based therapies for patients with ALS
  • Review the mechanism of action and clinical trial results of antisense oligonucleotides for the treatment of patients with ALS and SOD1 mutations
  • Identify challenges and opportunities in using shared decision-making to optimize care and quality of life for patients with ALS

Faculty

FACULTY_NAME

Terry D. Heiman-Patterson, MD

Professor of Neurology
Director MDA/ALS Center of Hope
Department of Neurology
Lewis Katz School of Medicine at Temple University
Philadelphia, PA

 

Accreditation/Credit Designation

Physicians’ Education Resource®, LLC is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Physicians’ Education Resource®, LLC designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Disclosures of Conflicts of Interest

Terry D. Heiman-Patterson, MD

  • Grant Research Support: Amylyx Pharmaceuticals Inc, Cytokinetics Inc, Mitsubishi Tanabe Pharma America Inc, and Orion Corp
  • Consultant: Biohaven Pharmaceuticals Inc, Cytokinetics Inc, ITF Pharma Inc, Mitsubishi Tanabe Pharma America Inc, and Samus Therapeutics

The staff of Physicians’ Education Resource®, LLC have no relevant financial relationships with ineligible entities.

PER® mitigated all COI for faculty, staff, and planners prior to the start of this activity by using a multistep process.

Instructions for Participation and Credit

  1. Complete the activity (including pre- and post-activity assessments).
  2. Answer the evaluation questions.
  3. Request credit using the drop-down menu.
You may immediately download your certificate.

 

Course Viewing Requirements

Supported Browsers:
Internet Explorer 8.0+ for Windows 2003, Vista, XP, Windows 7, Windows 8.1 and above
Google Chrome 28.0+ for Windows, Mac OS, or Linux
Mozilla Firefox 23.0+ for Windows, Mac OS, or Linux
Safari 6.0+ for Mac OSX 10.7 and above

Supported Phones & Tablets:
Android 4.0.3 and above
iPhone/iPad with iOS 6.1 or above

Off-Label Disclosure and Disclaimer

This activity may or may not discuss investigational, unapproved, or off-label use of drugs. Learners are advised to consult prescribing information for any products discussed. The information provided in this accredited activity is for continuing education purposes only and is not meant to substitute for the independent clinical judgment of a health care professional relative to diagnostic, treatment, or management options for a specific patient’s medical condition. The opinions expressed in the content are solely those of the individual faculty members and do not reflect those of PER® or any company that provided commercial support for this activity.